vs
Side-by-side financial comparison of BRT Apartments Corp. (BRT) and FENNEC PHARMACEUTICALS INC. (FENC). Click either name above to swap in a different company.
BRT Apartments Corp. is the larger business by last-quarter revenue ($24.3M vs $13.8M, roughly 1.8× FENNEC PHARMACEUTICALS INC.). BRT Apartments Corp. runs the higher net margin — -17.8% vs -34.7%, a 17.0% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 1.3%). Over the past eight quarters, BRT Apartments Corp.'s revenue compounded faster (1.9% CAGR vs -26.3%).
BRT Apartments Corp is a publicly traded real estate investment trust that owns, operates, and develops multi-family residential properties primarily across high-growth markets in the United States. Its core portfolio consists of garden-style and mid-rise apartment communities, serving diverse renter groups while targeting long-term asset value appreciation and stable dividend returns for its shareholders.
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
BRT vs FENC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $24.3M | $13.8M |
| Net Profit | $-4.3M | $-4.8M |
| Gross Margin | — | — |
| Operating Margin | -14.3% | -18.5% |
| Net Margin | -17.8% | -34.7% |
| Revenue YoY | 1.3% | 73.8% |
| Net Profit YoY | -108.7% | -141.1% |
| EPS (diluted) | $-0.23 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $24.3M | $13.8M | ||
| Q3 25 | $24.4M | $12.5M | ||
| Q2 25 | $24.2M | $9.7M | ||
| Q1 25 | $24.1M | $8.8M | ||
| Q4 24 | $24.0M | $7.9M | ||
| Q3 24 | $24.4M | $7.0M | ||
| Q2 24 | $23.9M | $7.3M | ||
| Q1 24 | $23.4M | $25.4M |
| Q4 25 | $-4.3M | $-4.8M | ||
| Q3 25 | $-2.7M | $-638.0K | ||
| Q2 25 | $-2.6M | $-3.2M | ||
| Q1 25 | $-2.4M | $-1.2M | ||
| Q4 24 | $-2.1M | $-2.0M | ||
| Q3 24 | $-2.2M | $-5.7M | ||
| Q2 24 | $-2.3M | $-5.6M | ||
| Q1 24 | $-3.2M | $12.8M |
| Q4 25 | -14.3% | -18.5% | ||
| Q3 25 | -13.7% | -1.5% | ||
| Q2 25 | -12.2% | -28.3% | ||
| Q1 25 | -11.3% | -9.2% | ||
| Q4 24 | -14.3% | -11.8% | ||
| Q3 24 | -11.7% | -74.6% | ||
| Q2 24 | -11.6% | -69.4% | ||
| Q1 24 | -14.0% | 54.2% |
| Q4 25 | -17.8% | -34.7% | ||
| Q3 25 | -11.1% | -5.1% | ||
| Q2 25 | -10.6% | -32.7% | ||
| Q1 25 | -9.8% | -13.3% | ||
| Q4 24 | -8.6% | -25.0% | ||
| Q3 24 | -9.0% | -82.2% | ||
| Q2 24 | -9.8% | -76.5% | ||
| Q1 24 | -13.5% | 50.6% |
| Q4 25 | $-0.23 | $-0.17 | ||
| Q3 25 | $-0.14 | $-0.02 | ||
| Q2 25 | $-0.14 | $-0.11 | ||
| Q1 25 | $-0.12 | $-0.04 | ||
| Q4 24 | $-0.10 | $-0.02 | ||
| Q3 24 | $-0.12 | $-0.21 | ||
| Q2 24 | $-0.13 | $-0.20 | ||
| Q1 24 | $-0.17 | $0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $25.1M | $36.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $177.2M | $35.5M |
| Total Assets | $709.8M | $70.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $25.1M | $36.8M | ||
| Q3 25 | $21.1M | $21.9M | ||
| Q2 25 | $23.6M | $18.7M | ||
| Q1 25 | $24.4M | $22.7M | ||
| Q4 24 | $27.9M | $26.6M | ||
| Q3 24 | $45.8M | $40.3M | ||
| Q2 24 | $18.9M | $43.1M | ||
| Q1 24 | $21.3M | $51.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | $19.4M | ||
| Q2 25 | — | $19.4M | ||
| Q1 25 | — | $19.4M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | — | $32.1M | ||
| Q2 24 | — | $31.8M | ||
| Q1 24 | — | $31.3M |
| Q4 25 | $177.2M | $35.5M | ||
| Q3 25 | $186.7M | $-4.5M | ||
| Q2 25 | $192.1M | $-7.5M | ||
| Q1 25 | $198.5M | $-5.9M | ||
| Q4 24 | $205.0M | $-5.9M | ||
| Q3 24 | $209.9M | $-5.2M | ||
| Q2 24 | $214.7M | $-1.4M | ||
| Q1 24 | $220.7M | $3.0M |
| Q4 25 | $709.8M | $70.6M | ||
| Q3 25 | $714.2M | $49.3M | ||
| Q2 25 | $699.6M | $44.9M | ||
| Q1 25 | $703.9M | $46.4M | ||
| Q4 24 | $713.5M | $44.9M | ||
| Q3 24 | $717.7M | $58.9M | ||
| Q2 24 | $694.7M | $63.2M | ||
| Q1 24 | $699.5M | $69.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 10.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.1M | $-6.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.1M | $-6.0M | ||
| Q3 25 | $9.1M | $1.5M | ||
| Q2 25 | $8.5M | $-3.7M | ||
| Q1 25 | $246.0K | $-4.3M | ||
| Q4 24 | $24.1M | $-1.5M | ||
| Q3 24 | $9.0M | $-2.2M | ||
| Q2 24 | $6.9M | $-8.4M | ||
| Q1 24 | $653.0K | $39.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 3.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BRT
| Unconsolidated Joint Ventures | $13.2M | 54% |
| Other | $11.1M | 46% |
FENC
Segment breakdown not available.
